Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 19/20 | 0.69 |
| ▸ | TACR2 | P21452 | 2/20 | 0.50 |
| ▸ | TACR3 | P29371 | 2/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.50 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30389940 | 1.00 | TRPV4 (0.69) | TRPV4TACR2TACR3KCNH2CACNA1C | |
| SCHEMBL30284179 | 0.94 | TRPV4 (0.68) | TRPV4TACR2TACR3KCNH2CACNA1C | |
| SCHEMBL25220089 | 0.94 | TRPV4 (0.68) | TRPV4TACR2TACR3KCNH2CACNA1C | |
| SCHEMBL6845623 | 0.94 | TRPV4 (0.79) | TRPV4TACR2TACR3KCNH2CACNA1C | |
| SCHEMBL30283994 | 0.91 | TRPV4 (0.75) | TRPV4TACR2TACR3KCNH2CACNA1C | |
| SCHEMBL2372259 | 0.91 | TRPV4 (0.75) | TRPV4TACR2TACR3KCNH2CACNA1C | |
| SCHEMBL2373626 | 0.89 | TRPV4 (0.87) | TRPV4TACR2TACR3KCNH2CACNA1C | |
| SCHEMBL30284325 | 0.89 | TRPV4 (0.87) | TRPV4TACR2TACR3KCNH2CACNA1C | |
| SCHEMBL2372315 | 0.89 | TRPV4 (0.70) | TRPV4TACR2TACR3KCNH2CACNA1C | |
| SCHEMBL2373125 | 0.88 | TRPV4 (0.79) | TRPV4TACR2TACR3KCNH2CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230255965-A1 | TRPV4 INHIBITOR AS A THERAPEUTIC AGENT FOR OCULAR DISEASES | RAQUALIA PHARMA INC. (JP) | 2023-08-17 | — | — | US | disclosed |
| EP-4183415-A1 | TRPV4 INHIBITOR AS THERAPEUTIC DRUG FOR EYE DISEASE | RaQualia Pharma Inc. (JP) | 2023-05-24 | — | — | EP | disclosed |
| WO-2011119704-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230255965-A1 | TRPV4 INHIBITOR AS A THERAPEUTIC AGENT FOR OCULAR DISEASES | TRPV4, TRPV5, TRPV2 | TRPV4 1/4885TACR2 314/4885TACR3 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.